Abstract
SB is important for DD because it can be used to rapidly identify the MoA of novel drugs, enabling companies to make go/no decisions earlier in the drug development process by avoiding pathways associated with toxicological or pharmacological issues. SB can reduce the number of compounds synthesized and manufactured owing to refined algorithms which avoid poor PK and toxic effects. In the longer term investments in SB will enable research institutions and companies to save time and money in the DD process by choosing drugs which are more likely to succeed in clinical development.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Kola I (2008) The state of innovation in drug development. Clin Pharmacol Ther 83(2):227–230
Nicholson JK (2006) Global systems biology, personalized medicine and molecular epidemiology. Mol Syst Biol 2:52
Grimaldi D, Claessens YE, Mira JP, Chiche JD (2009) Beyond clinical phenotype: the biologic integratome. Crit Care Med 37(1 Suppl):S38–S49
Hood L, Heath JR, Phelps ME, Lin B (2004) Systems biology and new technologies enable predictive and preventative medicine. Science 306(5696):640–643
Van der Greef J, McBurney RN (2005) Innovation: Rescuing drug discovery: in vivo systems pathology and systems pharmacology. Nat Rev Drug Discov 4(12):961–967
Ridgway D, Broderick G, Ellison MJ (2006) Accommodating space, time and randomness in network simulation. Curr Opin Biotechnol 17(5):493–498
Ozbabacan SEA, Gursoy A, Keskin O, Nussinov R (2010) Conformational ensembles, signal transduction and residue hot spots: Application to drug discovery. Curr Opin Drug Discov Develop 13(5):527–537
Schadt EE, Friend SH, Shaywitz DA (2009) A network view of disease and compound screening. Nat Rev Drug Discov 8(4):286–295
Materi W, Wishart DS (2007) Computational systems biology in drug discovery and development: methods and applications. Drug Discovery Today 12(7‐8)295–303
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2012 The Author(s)
About this chapter
Cite this chapter
Prokop, A., Michelson, S. (2012). Systems Biology: Impact on Pharma and Biotech. In: Systems Biology in Biotech & Pharma. SpringerBriefs in Pharmaceutical Science & Drug Development, vol 2. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-2849-3_11
Download citation
DOI: https://doi.org/10.1007/978-94-007-2849-3_11
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-2848-6
Online ISBN: 978-94-007-2849-3
eBook Packages: MedicineMedicine (R0)